Analyst: New Novo drug can defend huge business
The faster-acting insulin that Novo Nordisk submitted an EU application for late last week is not light-years ahead of current products, says an analyst, but there’s enough innovation in the product to help it defend one of the drug group’s most important markets.
BY STEFAN SINGH KAILAY
Friday’s announcement that Novo Nordisk had submitted an MAA to the European Medicines Agency for the company’s faster-acting insulin analogue hardly caught observers by surprise, but it is certainly great news for the group which has a massive business to defend.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
